Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Patients with end-stage renal disease (ESRD) who have elevated serum phosphate (P) levels
have significantly higher mortality rates compared to those with normal P. In patients
receiving conventional dialysis regimens, serum P may be lowered through dietary intervention
and use of P binders, though these have potentially important side effects and may adversely
impact quality of life. Whether lowering P, and / or targeting specific P levels improve
survival and clinical outcomes is unknown. Despite this uncertainty, over 90% of patients
with ESRD receive P lowering therapy and guidelines for the care of patients with ESRD are
increasingly calling for more aggressive phosphate lowering. This intensive P lowering
results in extra medications (and their associated side-effects), and higher health care
costs. We are uncertain whether the intensification of P control results in measurable
benefits to patients with ESRD. The overall goal of this pilot trial is to evaluate the
feasibility of conducting a randomized controlled trial of intensive vs liberalized phosphate
control among hemodialysis recipients.
Phase:
Phase 2
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto